Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis

Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis

  • Akshaya Srikanth Bhagavathula, 
  • Asim Ahmed Elnour, 
  • Shazia Qasim Jamshed, 
  • Abdulla Shehab



Spontaneous or voluntary reporting of suspected adverse drug reactions (ADRs) is one of the vital roles of all health professionals. In India, under-reporting of ADRs by health professionals is recognized as one of the leading causes of poor ADR signal detection. Therefore, reviewing the literature can provide a better understanding of the status of knowledge, attitude and practice (KAP) of Pharmacovigilance (PV) activities by health professionals.


A systematic review was performed through Pubmed, Scopus, Embase and Google Scholar scientific databases. Studies pertaining to KAP of PV and ADR reporting by Indian health professionals between January 2011 and July 2015 were included in a meta-analysis.


A total of 28 studies were included in the systematic review and 18 of them were selected for meta-analysis. Overall, 55.6% (95% CI 44.4–66.9; p<0.001) of the population studied were not aware of the existence of the Pharmacovigilance Programme in India (PvPI), and 31.9% (95% CI 16.3–47.4; p<0.001) thought that "all drugs available in the market are safe". Furthermore, 28.7% (95% CI 16.4–40.9; p<0.001) of them were not interested in reporting ADRs and 74.5%, (95% CI 67.9–81.9; p<0.001) never reported any ADR to PV centers.


There was an enormous gap of KAP towards PV and ADR reporting, particularly PV practice in India. There is therefore an urgent need for educational awareness, simplification of the ADR reporting process, and implementation of imperative measures to practice PV among healthcare professionals. In order to understand the PV status, PvPI should procedurally assess the KAP of health professionals PV activities in India.


India is home to one of the largest drug consuming populations in the world. There are between 60,000–80,000 brands of drugs available in the Indian market that are irrationally prescribed and misused [1]. This may be due to lack of medication safety practices, and failures in the regulatory environment. The misuse and faulty prescribing account for considerable development of adverse drug reactions (ADRs) that are one of the major causes of mortality and morbidity, unplanned hospitalization, and increased healthcare cost, worldwide [25]. Thus, early identification of ADRs is extremely important for both government and non-government health care organizations.

The World Health Organization (WHO) defines ADRs as any noxious, unintended, and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or treatment of the disease [6]. The worldwide incidence of ADR occurrence leading to emergency hospitalization ranges from 0.2 to 41.3%, while 28.9% of these ADRs are preventable [7]. In 2012, a meta-analysis showed that 52% of ADR-related emergency hospitalizations and 45% of ADRs in inpatients were preventable [8]. Moreover, post-marketing safety studies have been shown to be very important in identifying possible risk factors associated with the use of new drugs in the general population and the contribution of health professionals is significant in reporting suspected ADRs to strengthen signal detection.

Pharmacovigilance (PV) is and the sum of activities related to the detection, assessment, understanding, and prevention of ADRs caused by drugs [9]. Spontaneous reporting of suspected ADRs to PV centers is of utmost importance to generate the safety data of marketed drugs. Indeed, understanding the importance of reporting ADRs, national and international organizations urged health professionals to prioritize ADR reporting in order to curtail ADR- related problems. In India, the national Pharmacovigilance Programme of India (PvPI) was established by the Central Drugs Standard Control Organization (CDSCO) in 2004 to monitor ADRs and to provide drug safety reports to the WHO-ADR monitoring center in Uppsala, Sweden [10]. To coordinate ADR monitoring throughout India, the Drug Controller General of India (DCGI) and Indian Council of Medical Research (ICMR) have established many peripheral PV centers in various hospitals located in major Indian cities [11].

Furthermore, it is evident that under-reporting of suspected ADRs by health professionals is a widespread problem in India [12]. For instance, the contribution of ADR reporting from India was below 1%, which highlights the existing gaps in success of the PV programme [13]. There are several local and national projects that are aimed at improving and promoting PV activities in India [1418]. These initiatives seek to increase awareness of the PV programme among health professionals and to improve ADR reporting. In particular, a better understanding of these issues could help national organizations in developing strategies for improvement of PV activities. Hitherto, no systematic review on this topic was identified from India. In order to gather data from the existing evidence pertaining to knowledge, attitude and practice (KAP) of ADR reporting and PV in the health professionals, a systematic review of current literature and a meta-analysis were performed.

Materials and Methods

To summarize the existing evidence related to PV activities in India, a systematic review using Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statements was conducted (S1 Appendix). Cross-sectional observational studies investigating the KAP of PV activities in India were considered. Papers that are original peer-reviewed research articles published in English from January 2011- July 2015 were retrieved from four databases: Pubmed, Scopus, Embase and Google Scholar. We limited our review to studies that used a structured questionnaire administered to Indian health professionals (doctors, nurses, dentists, pharmacists, medical students, postgraduate residents) assessing the following:

  • Awareness of PvPI
  • Knowledge about the safety of drugs
  • Attitude towards reporting ADRs
  • Knowledge about obtaining ADR forms
  • Practice of ADR reporting
  • Availability of ADR forms
  • Surveys using open answers focused on health professionals

Data collection

Titles and abstracts were screened by one author (ASB). Studies were selected for inclusion from full-text articles by two researchers (ASB, AAE). The database search fields for titles, abstracts and index terms were searched using the following research string: pharmacovigilance* AND adverse drug reactions reporting* AND health professionals* AND survey* AND India* AND (knowledge OR attitude OR practice).

Selection of studies

Two authors (ASB and SQJ) analyzed the search results in collaboration to find potentially eligible studies. Small changes in wording were also overlooked for their exact functional meaning. We excluded duplicates and studies in which data was inadequately reported (Fig 1).

Fig 1. Flow of information through the different phases of the systematic review.

Data extraction

Two researchers independently performed the data extraction and disagreement was resolved by consensus. The extracted data was based on information reported in or calculated from the included studies. Corresponding authors were not contacted for unpublished information. Information including year of execution of the survey, sample size, study location, the method of administration of the questionnaire, and data towards KAP of PV and ADR reporting were retrieved. In particular, we considered six statements that were common to the different studies as outcomes for the meta-analysis:

  1. Respondent is aware of the National Pharmacovigilance Programme in India (percentage of inappropriate answers)
  2. Respondent considers all drugs to be safe (percentage of inappropriate answers)
  3. Respondent is interested in reporting ADRs (percentage of inappropriate answers)
  4. Respondent knows where to obtain ADR forms (percentage of inappropriate answers)
  5. Respondent never reported an ADR (percentage of yes)
  6. Respondent reports non-availability of ADR forms (percentage of yes)

The first two statements assessed the knowledge concerning the national PV programme and safety of drugs, statements three and four assessed the attitude towards ADR reporting, and the last two evaluated the practice of PV activities. Due to differences in the questionnaires administered in different studies, the information suitable to our purpose was extracted for analysis.

Statistical analysis

Meta-analysis was performed using statistical software StatsDirect 2.8.0 on all the studies that yielded comparable outcomes. Heterogeneity of the studies was evaluated using Cochrane's Q test and the I2 statistics. Random effects model was used to combine studies showing heterogeneity of Cochrane Q p<0.10 and I2>50% [19]. The methodological quality of studies was assessed using Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) scale [20].

To address the issue of heterogeneity of the studies, a sensitivity analysis was considered using the following subgroups:

  • studies of high quality (over 75% of the STROBE checklist)
  • studies of low quality (under 75% of the STROBE checklist)

Moreover, publication bias was assessed using Egger and Begg tests and graphs representing funnel plots.


A total of 320 studies were retrieved from the four scientific databases (Pubmed, Scopus, Embase and Google Scholar) for analysis. After screening titles and abstracts, for duplicates and irrelevant studies, 270 papers were excluded. Fifty studies were considered for the full text review, of which twenty-two were excluded as they did not meet the inclusion criteria (S2 Appendix). Finally, twenty-eight studies [2148] were selected for the systematic review and eighteen of these were included in the meta-analysis (Fig 1) [3148].

Study characteristics

All the 28 citations included in the systematic review were cross-section observational surveys using self-administered questionnaires conducted among Indian healthcare professionals and published between January 2011 and July 2015. Of these, one study was a web-based survey of pharmacists [38]. Eleven studies were conducted in south India [23,24,2627,2930, 3233,40,42], five in the western part of India [22,25,31,45,47], 3 studies in the capital city New Delhi [28,43,48], two in central India [21,37] and one study each was conducted in Bihar [34], Assam [36], Punjab [41], and Jaipur [46]. In addition, three studies did not specify their study location [35,38,44].

The sample size of the studies ranged from 42 [35] to 870 [45] surveyed health professionals. The main characteristics of 28 studies following the STROBE scale are summarized in Table 1. All of the 28 studies met the quality criteria and were selected for systematic review. However, in the meta-analysis, we only included 18 articles (total = 3,187 participants) that are indexed in Pubmed and Scopus that covered all of the main statements.

Table 1. Characteristics of Studies included for KAP-PV activities among health professionals in India.

Study results and meta-analysis

The number of inappropriate responses was considered for each statement regarding KAP of PV and ADR reporting.

Knowledge about PV and Drug safety in India.

Two statements were used in the assessment of knowledge regarding the awareness of existing PvPI and safety of drugs. Overall, 55.6% (95% CI 44.4–66.9; p<0.001) of the health professionals gave an incorrect answer to the statement "Are you aware of the existence of national pharmacovigilance programme in India" (Fig 2). In addition, 31.9% (95% CI 16.3–47.4; p<0.001) of the sample erroneously thought that "all drugs available in the market are safe" (Fig 3).

Fig 2. Awareness of existing Pharmacovigilance programme in India (PVPI), (% of inappropriate answer) 17 studies, N = 3145.

Fig 3. Respondents considered all drugs available in market are safe, (% of inappropriate answers) 7 studies, N = 1321.

Attitude of health professionals.

Attitude towards reporting ADRs were assessed using two statements. 28.7% (95% CI 16.4–40.9; p<0.001) participants declared that they were not interested in reporting ADRs to PV centers and 67% (95% CI 53.2–80.8; p<0.001) commented that they did not know where to obtain ADR reporting forms (Figs 4 and 5).

Fig 4. Respondents interest to report ADRs, (% of inappropriate answers) 11 studies, N = 1942.

Fig 5. Respondents know where to obtain ADR forms, (% of inappropriate answers) 8 studies, N = 1622.

ADR reporting practices.

To the statement "Had you ever reported an ADR to a PV center" nearly three-quarters (74.5%, 95% CI 67.9–81.9; p<0.001) of the sample declared that they never reported any ADR to PV centers and 40.8% (95% CI 17.4–64.3; p<0.001) of them ascribed it to "non-availability of ADR forms at their sites" (Figs 6 and 7).

Publication bias

Publication bias was not highlighted in any of the 18 studies analyzed. Based on Egger and Begg tests graph confirmed by the funnel plot.

Sensitivity analysis

Meta-analysis was stratified based on the quality of the studies (high and low quality) to reveal the KAP concerning PV activities in India. For the statement "Are you aware of the existence of PvPI" the percentage of high-quality studies incorrectly answered 55.3% (95%CI 39.2–71.2) compared to 53.5% (95%CI 37.8–69.1) low-quality studies. Furthermore, sensitivity analysis of the low-quality studies showed a negative attitude of 30.8% (95%CI 10.5–51.1) towards reporting ADRs as compared to the non-stratified groups. However, failure to report ADRs among health professionals was 76.7% (95%CI 64.0–89.3), higher than in the main analysis in high-quality studies.


This systematic review was aimed at assessing the KAP towards PV and ADR reporting in studies conducted in India during January 2011 to July 2015. To the best of our knowledge, this is the first systematic review and meta-analysis on this topic. In 2009, two reviews focused on under-reporting of ADRs [49] and PV steps in causality assessments [50].

Strengths and limitations

Our study is the first to execute the KAP of PV activities in India by including 18 studies in meta-analysis. This has helped us gather and strengthen the combination of each study results, providing stronger evidence about ongoing PV activities among Indian health professionals. Our search strategy was comprehensive, including studies published in English, and research using standard questionnaires conducted in India.

Summary of study findings

We found that more than 50% of the sample were not aware of PvPI and around 32% thought that all drugs available in market were safe (allopathic, herbal/traditional, blood products, biological and medical devices). Although 71.3% were interested in reporting suspected ADRs, 67% did not know where to obtain ADR reporting forms. Indeed, three-quarters of the sample never reported an ADR to any PV centers. Additionally, 40.8% declared that ADR reporting forms were not readily available at their sites to enable ADRs reporting. Overall, we found that more than 40% of the sample have demonstrated inadequate knowledge, attitude and more than half never actually reported an ADR to the PV centers.

The findings of our review identified the lack of knowledge regarding PV and drug safety in India. For instance, nearly 55% of the population answered incorrectly regarding the existence of PvPI in India. This is in agreement with the recent research conducted on 90 ADR monitoring centers working under PvPI which highlighted that 68% of the doctors, 80% of nurses and 81% of the pharmacists are unaware of PvPI in India [12]. Lack of awareness regarding the existence of PvPI may be an important deterrent to ADR reporting. In Bisht et al [51] intervention study, more than 50% of the CME (continuous medical education) attended doctors were unaware of existence of PvPI. Interestingly, doctors attending CME showed a higher resistance toward ADR reporting than non-CME attendees (57% versus 33%). To improve awareness among health professionals, various approaches were attempted during the past three years that include awareness lectures, public campaigns, conferences, workshops, post-training reminders such as periodic E-mails and SMS alerts [52].

The health professionals’ lack of knowledge regarding safety of marketed drugs could lead to serious drug reactions in patients. Remedies such as allopathic, ayurveda, homeopathy, unani, and other therapies are widely practiced in India. In 2012, the South Asian Association for Regional Cooperation (SAARC) reported that there are more than 4246 herbal drugs registered and available as over-the-counter without restrictions in India [53]. Furthermore, concerted use of allopathic and non-allopathic medications poses the risk of serious drug-drug interactions that may produce potential adverse outcomes. Hence, it is essential for all health professionals to study the safety profiles of medications before prescribing them and be vigilant in reporting any suspected ADRs to the PV centers. Reporting suspected ADRs for medications promotes a deeper understanding of their safety profile in a real clinical settings.

Further, it was clearly observed that a part of the health professionals (28.7%) were not interested in reporting suspected ADRs. This attitude showcases the passive perception of some of the health professionals ignoring the importance of reporting ADRs. Evidence from various national and international studies suggested that lethargy, diffidence, insecurity and overwork were some of the factors for under-reporting of ADRs by health professionals [12,49]. In particular, Desai and co-workers, described that 70% of their study participants did not know where to report the suspected ADRs [47]. Other studies also identified other reasons such as 'unreported could not make any difference' [51], 'lack of financial incentives' [30,38], 'ignorance (that only serious ADRs are to be reported)' [54] and 'lack of time' [55,56]. It is therefore necessary to motivate the health professionals by repetitive educational interventions and simplification of the ADR reporting process which might encourage health professionals to report ADRs in India. Importantly, making ADR reporting online is also recommended based on our findings.

Practice of PV is crucial for generating a national safety database of drugs. Our meta-analysis identified that a majority of the health professionals never reported any ADR encountered during their practice. The average Individual Case Safety reports (ISCRs) received per month by Vigiflow from 12 PV centers during the period of 2011 to 2013 was 48.3 and the rate of spontaneous reporting was only 33.8%. There are manifold hindering factors that need further investigation to understand the barriers influencing the practice of PV. Indeed, it is a difficult task to foster PV practice culture without proper knowledge and attitude. Possible solutions for improving PV practice in India might be implementing strong regulations to report ADRs after providing sufficient training to the health professionals and simplifying the process of ADR reporting using electronic system by giving some amount of financial incentives to health professionals.


This study has some limitations that should be considered. Our meta-analysis showed some heterogeneity with a consistent lack of homogeneity of the responses. This heterogeneity could be due to sociodemographic, inter-professional, and cultural variations among the health professionals across India. Moreover, there were differences in sample selection and the way questionnaires were administered that may lead to selection bias. In addition, questionnaires administered in all studies were open and closed-ended and the population studied may have overestimated or underestimated when responding which may have led to recall bias. Quality assessment and stratification of quality and geographic criteria have allowed the evaluation of the presence of potential bias and confounding. For instance, poor quality could influence the KAP regarding the real function of PV in India.


Our results identified a huge-gap pertaining to KAP towards PV activities in India. The fact that more than 75% of the health professionals never reported an ADR, raises questions on PV activities in India. Educational campaigns and training to improve the knowledge; financial incentives and simplifying the reporting process might change the attitudes. Further, making ADR reporting mandatory can make health professionals aware of the importance of PV in India. In order to better understand the PV progress, PvPI should periodically assess the KAP of health professionals PV activities in India.

Supporting Information


We thank Dr. Raessa Gupte, Ph.D and Dr. Shiri Diskin, Ph.D for their assistance in manuscript editing.

Author Contributions

Conceived and designed the experiments: ASB AAE. Performed the experiments: ASB AAE SQJ AS. Analyzed the data: ASB AAE. Contributed reagents/materials/analysis tools: ASB AAE SQJ AS. Wrote the paper: ASB.


  1. 1. Sengupta A. Universal Health care in India making it public. Ontario, Canada: IRDC; 2013 May p. 23. Report No.: 19.
  2. 2. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary care referral centre: a prospective study. BMC Pharmacol Toxicol 2007;7(1):8.
  3. 3. Rajakannan T, Mallayasamy S, Guddattu V, Kamath A, Vilakkthala R, Rao PG, et al. Cost of adverse drug reactions in a south Indian tertiary care hospital. J Clin Pharmacol 2012;52(4):559–565. pmid:21505086
  4. 4. Al Hamid A, Ghaled M, Aljadhey H, Aslanpour Z. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol 2014;78(2):202–217. pmid:24283967
  5. 5. Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adult and children and their impact on cost and hospital stay-a systematic review. Eur J Clin Pharmacol 2013;69(12):1985–1996. pmid:23955174
  6. 6. World Health Organization. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: World Health Organization 2002. HO/EDM/QSM/2002.2
  7. 7. Beijer HJ, de Blaey CJ. Hospitalizations caused by adverse drug reactions (ADRs): a meta-analysis of observational studies. Pharm World Sci 2002;24(2):46–54. pmid:12061133
  8. 8. Hakkarainen KM, Hedna K, Petzold M, Hagg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions- a meta-analysis. PLoS One 2012;7(3):e33236 pmid:22438900
  9. 9. World Health Organization (WHO). Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva World Health Organization. 2002. Available: Accessed 2015 Aug 14.
  10. 10. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: Complementing spontaneous reporting systems. Drug Saf 2013;36:75–81. pmid:23329541
  11. 11. Protocol of National Pharmacovigilance Programme, November 2004. CDSCO, Ministry of Health and Family Welfare, Government of India. November, 2004. Available:
  12. 12. Tandon VR, Mahajan V, Khajuria V, Gullani Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian J Pharmacol 2015;47(1):65–71. pmid:25821314
  13. 13. Prakash S. Pharmacovigilance in India. Indian J Pharmacol 2007;39(3):123.
  14. 14. Sanghavi DR, Dhande PP, Pandit VA. Perception of pharmacovigilance among doctors in tertiary care hospitals: influence of an interventional lecture. Int J Risk Saf Med 2012;25(4):197–204.
  15. 15. Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge attitude practice of pharmacovigilance among healthcare professionals in an Indian tertiary care teaching hospital. Int J PharmTech Res 2011;3(2):678–692.
  16. 16. Olsson S. Pharmacovigilance training with focus on India. Indian J Pharmacol 2008;40(Suppl 1):S28. pmid:21369410
  17. 17. Shankar PR, Subish P, Mishra P, Dubey AK. Teaching pharmacovigilance to medical students and doctors. Indian J Pharmacol 2006;38(5):316.
  18. 18. Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol 2007;39(3):124.
  19. 19. Haidich AB. Meta-analysis in medical research. Hippokratia 2010;14(Suppl 1):29–37. pmid:21487488
  20. 20. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344–349. pmid:18313558
  21. 21. Torwane NA, Hongal S, Gouraha A, Saxena E. Awareness related to reporting of adverse drug reactions among health caregivers: A cross-sectional questionnaire survey. J Nat Accred Board Hosp Healthcare Providers 2015;2:23–9.
  22. 22. Bansode AA, Zad VR, Sawant SD, Dudhal KS. Awareness about pharmacovigilance among resident doctors in a tertiary care hospital. J Evolution Med Dent Sci 2015;4(2):207–210.
  23. 23. Sridevi SA, Ganesh M. Knowledge, attitude and practice of pharmacovigilance among healthcare professionals of Chennai. Int J Pharmacol Toxicol 2014;4(3):151–154.
  24. 24. Kiran LJ, Shivashankaramurthy KG, Bhooma S, Dinakar K. Adverse drug reaction reporting among clinicians in a teaching hospital in south Karnataka. Scholars J App Med Sci 2014;2(1D):399–403.
  25. 25. Karelia BN, Piparava KG. Knowledge, attitude and practice of pharmacovigilance among healthcare professionals of Rajkot city. Int J Basic Clin Pharmacol 2014;3(1):50–3.
  26. 26. Chanchu S, Rathinavelu M. Health professionals knowledge, attitude and practice towards pharmacovigilance and adverse drug reactions in India. Int J Sci Res 2014;3(4):1434–1437.
  27. 27. Maharani B, Kalaiah P. Attitude and knowledge of medical practitioners at Salem towards pharmacovigilance reporting system. Nat J Basic Med Sci 2013;3(4):294–300.
  28. 28. Amrita P, Simar PS, Vineet K. Status of adverse drug reaction reporting by health care professionals of Delhi. Indian J Pharm Pract 2012;5(4):42–50.
  29. 29. Kumar MB, Sandeep P, Soumya M. A survey on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related issues. Indian J Pharm Pract 2012;5(4):51–55.
  30. 30. Kamtane R, Jayawardhani V. Knowledge, attitude and perception of physicians towards adverse drug reaction (ADR) reporting: A pharmacoepidemiological study. Asian J Pharm Clin Res 2012;5(3):210–214.
  31. 31. Upadhyaya HB, Vora MB, Nagar JG, Patel PB. Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of Tertiary Care Hospital in Gujarat. J Adv Pharm Technol Res 2015;6(1):29–34. pmid:25709967
  32. 32. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res 2015;6(1):45–52. pmid:25657902
  33. 33. Ravinandan AP, Achutha V, Ramani VK, Uttangi S, Kumar SL. Study of knowledge, attitude, and practice of pharmacists towards adverse drug reaction reporting in Davangere city. Asian J Pharm Clin Res 2015;8(3):262–265
  34. 34. Panja B, Bhowmick S, Chowrasia VR, Bhattacharya S, Chatterjee RN, Sen A, et al. A cross-sectional study of adverse drug reactions reporting among doctors of a private medical college in Bihar, India. Indian J Pharmacol 2015;47(1):126–127. pmid:25821329
  35. 35. Aithal S, Hooli TV, Varun HV. Knowledge and attitude about adverse drug reactions reporting among doctors at a tertiary care hospital. Int J Pharm Bio Sci 2014;5(1):108–113.
  36. 36. Gupta P, Anvikar AR, Valecha N, Gupta YK. Pharmacovigilance practices for better healthcare delivery: Knowledge, and attitude study in the national malaria control programme in India. Malar Res Treat 2014:837427. pmid:25302133
  37. 37. Khan SA, Goyal C, Chandel N, Raif M. Knowledge, attitude, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. J Nat Sci Biol Med 2013;4(1):191–196. pmid:23633861
  38. 38. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res 2013;4(4):204–10. pmid:24312887
  39. 39. Thomas TM, Udaykumar P, Scandashree K. Knowledge, attitude, and practice of adverse drug reaction reporting among doctors in a tertiary health care centre in South India. Int J Pharmacol Clin Sci 2013;2(3):82–88.
  40. 40. Choudary AK, Nivedhitha S, Radhakrishna L, Tirumalaikolundusubrimnian P, Manicvasagam S. Perception of adverse drug reaction among doctors, nurses, and pharmacists of a tertiary care rural teaching hospital. Internet J Pharmacol 2013; 12(1):1566.
  41. 41. Hardeep L, Bajaj JK, Rakesh K. A survey on the knowledge, attitude and the practice of pharmacovigilance among the health care professionals in a teaching hospital in northern India. J Clin Diagn Res 2013;7(1):97–9. pmid:23449824
  42. 42. Prakasam A, Nidamanuri A, Kumar S. Knowledge, perception and practice of pharmacovigilance among community pharmacists in South India. Pharm Pract 2012;10(2):222–226.
  43. 43. Rehan HS, Sah RK, Chopra D. Comparison of knowledge, attitude and practices of resident doctors and nurses on adverse drug reaction monitoring and reporting in a tertiary care hospital. Indian J Pharmacol. 2012;44(6):699–703. pmid:23248397
  44. 44. Pimpalkhute SA, Jaiswal KM, Sontakke SD, Bajait CS, Gaikwad A. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring in resident doctors of a tertiary care teaching hospital. Indian J Med Sci 2012;66(3–4):55–61. pmid:23603621
  45. 45. Kharkar M, Bowalekar S. Knowledge, attitude and perception/practices (KAP) of medical practitioners in India towards adverse drug reaction (ADR) reporting. Perspect Clin Res. 2012;3(3):90–4. pmid:23125959
  46. 46. Upadhyaya P, Seth V, Moghe VV, Sharma M, Ahmad M. Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college. Ther Clin Risk Manag 2012;8:307–312. pmid:22767994
  47. 47. Desai CK, Iyer G, Panchal J, Shah S, Dikshit RK. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res. 2011;2(4):129–36. pmid:22145123
  48. 48. Chopra D, Wardhan N, Rehan HS. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital. Int J Risk Saf Med. 2011;23(4):227–32. pmid:22156087
  49. 49. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Saf 2009;32(1):19–31. pmid:19132802
  50. 50. Rehan HS, Chopra D, Kakkar AK. Physicians guide to pharmacovigilance terminology and causality assessment. Eur J Int Med 2009;20(1):3–8.
  51. 51. Bisht M, Singh S, Dhasmana DC. Effect of educational intervention on adverse drug reporting by physicians: A cross-sectional study. ISRN Pharmacol. 2014;259476. pmid:25006492
  52. 52. Sake SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online J Public Health Inform 2015;7(2):e223. pmid:26392851
  53. 53. Regulatory scenario for herbal supplements in India and other SAARC countries, June 2012. Available: Accessed 2013 Aug 19.
  54. 54. Mishra H, Kumar V. Pharmacovigilance: current scenario in a tertiary care teaching medical college in north India. J Pharmacovigil 2013;1(2):108.
  55. 55. Rishi RK, Patel RK, Bhandari A. Under reporting of ADRs by medical practitioners in India—results of pilot study. Adv Pharmacoepidem Drug Saf 2012;1(3):112.
  56. 56. Lahite RJ, Lahkar M. An update on the pharmacovigilance programme in India. Front. Pharmacol. 2015.